Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HypoPro
NCT06772441Phase 2Recruiting
- Start
- Nov 2024
- Primary completion
- Oct 2026
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of goserelin in prostate cancer (PCa). Started Nov 2024; status: recruiting.
02
Drugs
goserelin
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT06772441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06772441.